Amanda Mocroft, Andrew Phillips, Alessandro Cozzi Lepri, Colette Smith, Daniel Grint
The EuroSIDA study is a prospective observational cohort study of more than 14.200 patients followed in 93 hospitals in 31 European Countries plus Israel and Argentina. The main objective of the study is to assess the impact of antiretroviral drugs on the outcome of the general population of HIV-infected patients living in Europe. The study is funded by the European Commission until 2010 and by unrestricted grants from Bristol-Myers Squibb, GlaxoSmithKline, Roche, Gilead, Pfizer, Merck and Co., Tibotec and Boehringer-Ingelheim. The study is led by by Prof. Jens Lundgren (firstname.lastname@example.org) and coordinated by Dr Ole Kirk (email@example.com) from the Copenhagen HIV Project. Further information about the EuroSIDa study is available at www.cphiv.dk.
Click here to go back to the list of studies in the HIV Epidemiology and Biostatistics Group.
Page last modified on 17 apr 13 15:30